Case report of penile cancer recurrence treated with cetuximab combined with anlotinib

Shuang Dai; Yan-Yang Liu; Tao Liu; Yu Zhang; De-Yun Luo

doi:10.1002/ccr3.5443

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib

Clin Case Rep. 2022 Feb 15;10(2):e05443. doi: 10.1002/ccr3.5443. eCollection 2022 Feb.

Authors

Shuang Dai¹, Yan-Yang Liu¹, Tao Liu², Yu Zhang³, De-Yun Luo⁴

Affiliations

¹ Lung Cancer Center Department of Medical Oncology West China Hospital Sichuan University Chengdu China.
² Department of Oncology The First Affiliated Hospital of Chengdu Medical College Chengdu Medical College Chengdu China.
³ Department of Pathology West China Hospital Sichuan University Chengdu China.
⁴ Department of Abdominal Oncology West China Hospital Sichuan University Chengdu China.

Abstract

Penile squamous cell carcinoma with pelvic lymph node metastases/recurrence has a poor prognosis. We reported a case with recurrent pSCC was administered cetuximab and anlotinib after failure of first-line treatment and achieved an effective response. Cetuximab combined with anlotinib may be a new choice for relapsed pSCC.

Keywords: chemotherapy; metastases; penial squamous cell carcinoma; recurrence; targeted therapy.

Publication types

Case Reports